open access

Vol 14, No 3 (2017)
Prace oryginalne - nadesłane
Published online: 2017-10-06
Get Citation

Psychotic disorders related with use of novel psychoactive substances

Magdalena Kaizer-Będkowska, Krzysztof Kucia
Psychiatria 2017;14(3):162-167.

open access

Vol 14, No 3 (2017)
Prace oryginalne - nadesłane
Published online: 2017-10-06

Abstract

INTRODUCTION: The use of psychoactive substances has become an increasing social and medical problem. The problem is both their availability and variable composition together with hard to predict health effects.

MATERIAL AND METHODS: The materials used in the publication were obtained by searching the PubMed database for the following keywords: „novel psychoactive substances”, „new psychoactive substances”, „NPS”, „legal highs”, „smart drugs”, „bath salts”, „psychoactive drugs” „designer drugs”, „internet drugs”, „synthetic catinones”, „synthetic cannabinoids”, „novel psychoactive substances AND psychosis”, „new psychoactive substances AND psychosis”, „legal highs AND psychosis”, „legal highs AND psychosis”. Materials published until the January 2017 were taken for the analysis.

RESULTS: The article describes classification of the new psychoactive substances based on type of chemicals. There were described their working mechanisms and related psychophysical effects. Present research and case studies were also presented. In addition to the symptoms of the nervous system or cardiovascular system, a number of symptoms of psychiatric disorders such as hallucinations, delusions, agitation, aggressive behavior, sleep and wakefulness disorders, anxiety and affective disorders have been described. Frequency and severity of symptoms were often dependent on the type of substance and the dose taken. Some of the cases described required hospitalization.

CONCLUSIONS: Issues related to the novel psychoactive substances are related to the availability of these substances, the amount of the substances belonging to this group, the ease of synthesizing new agents and to the limited possibilities of labeling these substances. The use of this group of substances can cause various symptoms of psychiatric disorders, not specific for chemical substance.

Abstract

INTRODUCTION: The use of psychoactive substances has become an increasing social and medical problem. The problem is both their availability and variable composition together with hard to predict health effects.

MATERIAL AND METHODS: The materials used in the publication were obtained by searching the PubMed database for the following keywords: „novel psychoactive substances”, „new psychoactive substances”, „NPS”, „legal highs”, „smart drugs”, „bath salts”, „psychoactive drugs” „designer drugs”, „internet drugs”, „synthetic catinones”, „synthetic cannabinoids”, „novel psychoactive substances AND psychosis”, „new psychoactive substances AND psychosis”, „legal highs AND psychosis”, „legal highs AND psychosis”. Materials published until the January 2017 were taken for the analysis.

RESULTS: The article describes classification of the new psychoactive substances based on type of chemicals. There were described their working mechanisms and related psychophysical effects. Present research and case studies were also presented. In addition to the symptoms of the nervous system or cardiovascular system, a number of symptoms of psychiatric disorders such as hallucinations, delusions, agitation, aggressive behavior, sleep and wakefulness disorders, anxiety and affective disorders have been described. Frequency and severity of symptoms were often dependent on the type of substance and the dose taken. Some of the cases described required hospitalization.

CONCLUSIONS: Issues related to the novel psychoactive substances are related to the availability of these substances, the amount of the substances belonging to this group, the ease of synthesizing new agents and to the limited possibilities of labeling these substances. The use of this group of substances can cause various symptoms of psychiatric disorders, not specific for chemical substance.

Get Citation

Keywords

new psychoactive substances, psychotic disorders, NPS

About this article
Title

Psychotic disorders related with use of novel psychoactive substances

Journal

Psychiatria (Psychiatry)

Issue

Vol 14, No 3 (2017)

Pages

162-167

Published online

2017-10-06

Bibliographic record

Psychiatria 2017;14(3):162-167.

Keywords

new psychoactive substances
psychotic disorders
NPS

Authors

Magdalena Kaizer-Będkowska
Krzysztof Kucia

References (22)
  1. Urban M, Rudecki T, Wróblewski D, et al. Zaburzenia psychotyczne związane z przewlekłym przyjmowaniem mefedronu. Opis przypadku Pychiatr Pol. 2011; 45(3): 431–437.
  2. Ustawa z dnia 29 lipca 2005 r. o przeciwdziałaniu narkomanii. Tekst jednolity z dnia 26 stycznia 2016r. (Dz. U. z 2016 r. poz. 224).
  3. Mazurkiewicz MR, Głogowski M, Mrowińska D, et al. Ocena rozpowszechnienia, powodów i form użycia tak zwanych „dopalaczy” przez uczestników ankiety internetowej. Psychiatr Pol. 2013; 47(3): 1143–1155.
  4. McNabb CB, Russell BR, Caprioli D, et al. Single chemical entity legal highs: assessing the risk for long term harm. Curr Drug Abuse Rev. 2012; 5(4): 304–319.
  5. Khaled SM, Hughes E, Bressington D, et al. The prevalence of novel psychoactive substances (NPS) use in non-clinical populations: a systematic review protocol. Syst Rev. 2016; 5(1): 195.
  6. Iversen L, Gibbons S, Treble R, et al. Neurochemical profiles of some novel psychoactive substances. Eur J Pharmacol. 2013; 700(1-3): 147–151.
  7. Smith JP, Sutcliffe OB, Banks CE. An overview of recent developments in the analytical detection of new psychoactive substances (NPSs). Analyst. 2015; 140(15): 4932–4948.
  8. James D, Adams RD, Spears R, et al. Clinical characteristics of mephedrone toxicity reported to the UK National Poisons Information Service. Emergency Medicine Journal. 2010; 28(8): 686–689.
  9. Gibbons S. 'Legal highs' ― novel and emerging psychoactive drugs: a chemical overview for the toxicologist. Clin Toxicol (Phila). 2012; 50(1): 15–24.
  10. Adamowicz P, Gieroń J. Acute intoxication of four individuals following use of the synthetic cannabinoid MAB-CHMINACA. Clin Toxicol (Phila). 2016; 54(8): 650–654.
  11. Wood DM, Dargan PI. Novel psychoactive substances: how to understand the acute toxicity associated with the use of these substances. Ther Drug Monit. 2012; 34(4): 363–367.
  12. Schifano F, Papanti DG, Orsolini L, et al. Novel psychoactive substances: the pharmacology of stimulanys and hallucinogens. Expert Rev Clin Pharmacol. 2016; 9(7): 943–954.
  13. Corazza O, Schifano F, Farre M, et al. Designer drugs on the internet: a phenomenon out-of-control? the emergence of hallucinogenic drug Bromo-Dragonfly. Curr Clin Pharmacol. 2011; 6(2): 125–129.
  14. Iversen L, Gibbons S, Treble R, et al. Neurochemical profiles of some novel psychoactive substances. Eur J Pharmacol. 2013; 700(1-3): 147–151.
  15. Wikström M, Holmgren P, Ahlner J. A2 (N-benzylpiperazine) a new drug of abuse in Sweden. J Anal Toxicol. 2004; 28(1): 67–70.
  16. Lee H, Wang GY, Curley LE, et al. Acute effects of BZP, TFMPP and the combination of BZP and TFMPP in comparison to dexamphetamine on an auditory oddball task using electroencephalography: a single-dose study. Psychopharmacology (Berl). 2016; 233(5): 863–871.
  17. Schifano F, Orsolini L, Duccio Papanti G, et al. Novel psychoactive substances of interest for psychiatry. World Psychiatry. 2015; 14(1): 15–26.
  18. Hohman N, Mikus G, Czock D. Effects and risks associeted with novel psychoactive substances. Dtsch. Arztebl. Int. 2014; 111(9): 139–147.
  19. Murray DB, Potts S, Haxton C, et al. 'Ivory wave' toxicity in recreational drug users; integration of clinical and poisons information services to manage legal high poisoning. Clin Toxicol (Phila). 2012; 50(2): 108–113.
  20. Chan WL, Wood DM, Hudson S, et al. Acute psychosis associated with recreational use of benzofuran 6-(2-aminopropyl)benzofuran (6-APB) and cannabis. J Med Toxicol. 2013; 9(3): 278–281.
  21. Hill SL, Najafi J, Dunn M, et al. Clinical toxicity following analytically confirmed use of the synthetic cannabinoid receptor agonist MDMB-CHMICA. A report from the Identification Of Novel psychoActive substances (IONA) study. Clin Toxicol (Phila). 2016; 54(8): 638–643.
  22. Archer RP, Treble R, Williams K. Reference materials for new psychoactive substances. Drug Test Anal. 2011; 3(7-8): 505–514.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Psychiatria dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest Via Medica sp. z o.o. sp. komandytowa, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl